A Cambridge biotech has taken over development of a Roche rare disease drug, Cue Biopharma signed a deal with Boehringer ...

The finding means that building larger AI models for protein design, and feeding them more data, will produce predictably ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...

The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr.’s ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

With tariffs pushing manufacturing home to the U.S., Pitchbook warns of reduced M&A activity and venture capital funding.

“We were given the opportunity to engage with Genentech in 1977, two years before its IPO [initial public offering], and we ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...